Truist analyst Srikripa Devarakonda raised the firm’s price target on Cytokinetics (CYTK) to $84 from $70 and keeps a Buy rating on the shares. Following recent approval with a differentiated label, the firm thinks MYQORZO is poised to generate significant revenue in obstructive hypertrophic cardiomyopathy. Truist has updated its model and points out worldwide peak sales for oHCM alone of $3.7B vs. $3.8B consensus. The firm anticipates a steady MYQORZO launch in early 2026 that it believes should perform at least as well as Camzyos’s launch.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics price target raised to $83 from $73 at Leerink
- Cytokinetics price target raised to $95 from $87 at RBC Capital
- Cytokinetics (CYTK): Myqorzo’s Differentiated Profile, Global Upside, and Pipeline Catalysts Support Raised Target and Buy Rating
- Cytokinetics price target raised to $99 from $95 at Goldman Sachs
- Cytokinetics price target raised to $88 from $78 at Citizens